What are the anticoagulation recommendations for the Mitroflow Aortic Pericardial Heart Valve?
Extensive published data suggests that some form of anticoagulation therapy may be beneficial after bioprosthetic cardiac valve replacement in order to reduce the risk of thromboembolic phenomena. In general, for bioprostheses, consideration should be given to anticoagulation therapy for 30 to 60 days after aortic replacement. For patients with moderate to severe atrial enlargement, atrial fibrillation, left atrial thrombus, left atrial wall calcification or other atrial wall abnormalties, or a prior history of thromboembolic events, consideration should be given to prescribing indefinite anticoagulation therapy.
